Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well bortezomib works in treating patients with
metastatic thyroid cancer that did not respond to radioactive iodine therapy. Bortezomib may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth